Drug Discovery@nature.com 26 October 2012

Advertisement 4 GETS YOU 10 Save 10% on any package of 4 gene targeting projects. Scientists from the same organization can combine their orders to achieve discounts. Learn more. TABLE OF CONTENTS 26 October 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement From Molecular Systems Biology The genomes of many microbial pathogens have been studied to help identify effective drug targets and novel drugs, such efforts haven't yet reached full fruition. Here the authors report a systems biological approach that efficiently utilizes genomic information for drug targeting and discovery. Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery OPEN Hyun Uk Kim et al   News Top Drug firm to share raw trial data doi:10.1038/490322a Full disclosure could improve health care and restore trust. Full Text Hantavirus treatments advance amidst outbreak in US park doi:10.1038/nm1012-1448a Research into treatments for the rare but often fatal lung disease caused by New World hantaviruses may be paying off. Full Text US presidential candidates diverge on how to help biopharma doi:10.1038/nm1012-1445 Obama believes that bolstering government-funded research will extend America's edge in biopharmaceuticals, whereas Romney believes that corporate tax breaks will encourage companies to thrive. Full Text Social networks attempt to spark academic–university collaborations doi:10.1038/nbt1012-901 The creation of Knode may signal a growing appetite for internet-based systems that help industry scientists interact with and identify partners in academic labs. Full Text Analysis Top Taking the fat out of cancer doi:10.1038/scibx.2012.1071 An antibody targeting endotrophin, a fat cell–derived extracellular protein, has reduced growth of breast tumors in mice. The team will next study the antibody in animal models of obesity-induced cancer and test a humanized version in human cancer samples. Full Text From the analyst's couch: Autism spectrum disorders doi:10.1038/nrd3771 This analysis looks at the increasing number of candidates in the pipeline for autism spectrum disorders, reflecting the increasing prevalence of autism and the growing interest in finding novel treatments. Full Text Research Highlights Top Neurodegenerative diseases: Anti-epileptic drug shows benefit in AD mouse model doi:10.1038/nrd3850 Using a mouse model engineered to overexpress human amyloid precursor protein and amyloid-β, researchers have shown that cognitive and synaptic deficits are caused by aberrant neuronal network activity, and that this can be improved with an anti-epileptic drug. Full Text Vaccines: Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine? doi:10.1038/nrd3854 A new vaccine platform based on self-amplifying RNA encapsulated in synthetic lipid nanoparticles overcomes some of the limitations of earlier nucleic-acid-based approaches. Full Text Metabolic disorders: Safe cannabinoid receptor modulators in sight? doi:10.1038/nrd3851 A peripherally selective CB1R inverse agonist can safely and effectively reduce body weight in a mouse model of obesity, without affecting behaviour. Full Text Research & Reviews Top Targeting the TGFβ signalling pathway in disease doi:10.1038/nrd3810 This Review considers why the TGFβ signalling pathway is a drug target, the potential clinical applications of TGFβ inhibition, the issues arising with anti-TGFβ therapy and how these might be tackled. Full Text Targeting cells in chronic inflammation doi:10.1038/nrd3794 This Review focuses on the current knowledge of the IL-17–TH17 cell pathway to better understand the positive as well as potential negative consequences of targeting them. Full Text Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract doi:10.1038/nm.2932 Researchers describe a molecular cascade whereby mutant androgen receptor upregulates CGRP in neuronal cells, promoting JNK activation and degeneration. The 5-HT1B/1D receptor agonist naratriptan decreases CGRP expression and improves motor performance in a mouse model of SBMA. Full Text Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function doi:10.1038/nchembio.1081 Researchers propose that compounds binding a newly discovered allosteric site of the hepatitis C virus's NS3 protein may inhibit its function, and thus represent a new class of direct-acting antiviral agents. Full Text Drug Discovery JOBS of the week Postdoctoral Fellow in Nanomedicine and Drug Delivery Nanyang Technological Univeristy, School of Chemical and Biomedical Engineering Drug Development Project Manager Cancer Research UK Scientist / Sr Scientist – Oncology Drug Discovery H3 Biomedicine Laboratory Head Drug Metabolism within Early and Investigative Drug Disposition and Safety (eiDDS) F. Hoffmann-La Roche AG Drug Discovery Programme - Head of Biology Beatson Institute for Cancer Research More Science jobs from Drug Discovery EVENT Eleventh International Congress on Drug Therapy in HIV Infection 11.-15.11.12 Glasgow, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.